Perampanel exhibits anticonvulsant action against pentylentetrazol-induced seizures in immature rats

Epilepsy Res. 2021 Jan:169:106523. doi: 10.1016/j.eplepsyres.2020.106523. Epub 2020 Dec 1.

Abstract

Perampanel is a new antiepileptic drug with unique mechanism of action - antagonism of AMPA receptors. Its action in immature animals is not yet sufficiently known therefore we started to study anticonvulsant action of perampanel pretreatment (1-20 mg/kg i.p.) against seizures elicited by pentylenetetrazol. Three age groups of rats were examined - 12, 18 and 25 days old. Perampanel selectively suppressed the tonic phase of generalized seizures in the two younger groups and whole tonic-clonic seizures in the 25-day-old group. It exhibited also an anticonvulsant action against minimal clonic seizures present in control 18- and 25-day-old rats. Perampanel is an effective anticonvulsant drug even at very early stages of brain development.

Keywords: AMPA receptors; Pentylenetetrazol; Perampanel; Postnatal development; Rat.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use
  • Nitriles
  • Pentylenetetrazole / toxicity
  • Pyridones
  • Rats
  • Rats, Wistar
  • Seizures* / chemically induced
  • Seizures* / drug therapy

Substances

  • Anticonvulsants
  • Nitriles
  • Pyridones
  • perampanel
  • Pentylenetetrazole